| abstract |
This disclosure is related to llama-derived nanobodies of which the corresponding sequences are provided, corresponding to the variable domain (VHH) of llama heavy chain antibodies recognizing epitopes of the Spike protein of SARS-CoV-2, some of them, directed to the receptor binding domain, RBD. The nanobodies disclosed herein have important scientific significance and application prospects, they can be labeled or fused with fluorochromes and enzymes to be used as reagents for immunodetection of the virus. Most importantly, the disclosed nanobodies can be used in the development of a bio-drug for the prevention and clinical treatment of infection and diseases caused by SARS-CoV-2. |